Bio Molecular Industries Sdn Bhd (herein after refered to BioM) is a company incorporated in Malaysia under the Companies Act, 1965 on 11 May 2005 with its registered office at Unit B-05-3A, 5th Floor, Block B (West Wing) PJ8 Office Suite No. 23, Jalan Barat, Seksyen 8, 46050 Petaling Jaya, Selangor Darul Ehsan. BioM is an associate company of Masteel and as the date of the Agreement, the issued and paid up capital of BioM is 10,000,000 ordinary share of RM1.00 each. BioM is principally engaged in the business of manufacturing and research and development of radioisotopes and radiophamaceuticals products for Positron Emission Tomography (PET). BioM has also been awarded as a “BioNexus Status Company” by the Malaysian Biotechnology Corporation Sdn Bhd.

IBA is a company incorporated under the laws of the Kingdom of Belgium having its principal office at Chemin du Cyclotron 3, 1348 Louvain-la-Neuve, Belgium and a wholly-owned subsidiary of Ion Beam Application S.A. (“IBA SA”). IBA SA is listed on the pan-European stock exchange EURONET, and is included in the BelMid Index. IBA SA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, the company is also active in the field of industrial sterilisation and ionisation.


IBA Pharma was acquired by SK Capital Partners in 2012 and was subsequently acquired by CapVest Investment Fund in March 2016. The last acquisition has led to rebranding of IBA Molecular to Curium Pharma.


BioM has increased its paid-up share capital to RM20,120,000. Masteel’s shareholding in BioM had increased to 48.25% of the issued and paid-up share capital of BioM.